Eosinophilic Granulomatosis with Polyangiitis Relapse after COVID-19 Vaccination: A Case Report

We here describe the case of a 71-year-old Caucasian woman previously diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA) that had been treated with Mepolizumab, an anti-IL5 monoclonal antibody, since 2019 with a good clinical response. She had a mild COVID-19 in December 2020 and sh...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2022-01, Vol.10 (1), p.13
Main Authors: Costanzo, Giulia, Ledda, Andrea Giovanni, Ghisu, Alessandra, Vacca, Matteo, Firinu, Davide, Del Giacco, Stefano
Format: Article
Language:English
Subjects:
Asthma
Autoimmune diseases
Case Report
Case reports
Coronaviruses
COVID-19
COVID-19 vaccines
Disease
Dyspnea
EGPA
Granulomatosis
Infections
Influenza
Interleukin 5
Leukocytes (eosinophilic)
Medical imaging
Monoclonal antibodies
mRNA
mRNA BNT162b2 vaccine
mRNA vaccines
Myalgia
Patients
Pneumonia
Psoriasis
relapse
Respiration
Severe acute respiratory syndrome coronavirus 2
Steroids
Vaccination
vaccine
Viral infections
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We here describe the case of a 71-year-old Caucasian woman previously diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA) that had been treated with Mepolizumab, an anti-IL5 monoclonal antibody, since 2019 with a good clinical response. She had a mild COVID-19 in December 2020 and she tested negative for SARS-CoV-2 infection in only late January 2021. In April 2021 she received the first dose of mRNA BNT162b2 vaccine. Ten days later she developed myalgia, dyspnea and numbness of the limbs due to a relapse of EGPA that occurred during Mepolizumab treatment.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines10010013